Antibiotics
Catalog | Product Name / CAS / Description | Structure |
---|---|---|
BBF-01529 |
Kapurimycin A1 (132412-65-8) Inquiry |
|
It is originally isolated from Str. sp. DO-15. Kapurimycin A1 can resist gram-positive bacteria and a few gram-negative bacteria. |
||
BBF-01530 |
Kapurimycin A2 (132412-64-7) Inquiry |
|
It is originally isolated from Str. sp. DO-15. Kapurimycin A2 can resist gram-positive bacteria and a few gram-negative bacteria. |
||
BBF-01531 |
Kapurimycin A3 (129966-45-6) Inquiry |
|
It is originally isolated from Str. sp. DO-15. Kapurimycin A3 can resist gram-positive bacteria and a few gram-negative bacteria. |
||
BBF-01532 | ||
Karalicin is produced by the strain of Pseudomonus fluorescens/putida SS-3. It inhibits herpes simplex virus HSV-1, HSV-2, vaccinia virus, polio virus type I with the IC50 (μg/mL) of 0.004, 0.008, 0.016 and 0.016. |
||
BBF-01533 |
Katanosin A (116103-86-7) Inquiry |
|
Katanosin A is a peptide antibiotic originally isolated from Cytophaga sp. PBJ-5356. It has anti-gram-positive bacterial effect. |
||
BBF-01534 |
Lysobactin (118374-47-3) Inquiry |
|
Lysobactin, also known as katanosin B, is a potent antibiotic with in vivo efficacy against Staphylococcus aureus and Streptococcus pneumoniae. It was previously shown to inhibit peptidoglycan (PG) biosynthesis. |
||
BBF-01535 |
Kerriamycin A (98474-20-5) Inquiry |
|
Produced by the strain of Str. Violaceolatus, Kerriamycin A has anti-gram-positive bacterial effect and can also prolong the survival time of patients with Ai's ascites cancer. |
||
BBF-01536 |
Kerriamycin C (98495-38-6) Inquiry |
|
It is produced by the strain of Str. Violaceolatus. Kerriamycin C has anti-gram-positive bacterial effect and can also prolong the survival time of patients with Ai's ascites cancer. |
||
BBF-01538 |
Kibdelin A (103528-50-3) Inquiry |
|
Kibdelin A is originally isolated from Kibdelosporangium aridum subsp. largum SKF AAD-609. Kibdelin A is resistant to gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as vancomycin. |
||
BBF-01539 |
Kibdelin B (103528-49-0) Inquiry |
|
Kibdelin B is originally isolated from Kibdelosporangium aridum subsp. largum SKF AAD-609. Kibdelin B is resistant to gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as vancomycin. |
||
BBF-01540 |
Kibdelin C1 (103549-47-9) Inquiry |
|
Kibdelin C1 is originally isolated from Kibdelosporangium aridum subsp. largum SKF AAD-609. Kibdelin C1 is resistant to gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as vancomycin. |
||
BBF-01541 |
Kibdelin C2 (105997-85-1) Inquiry |
|
Kibdelin C2 is originally isolated from Kibdelosporangium aridum subsp. largum SKF AAD-609. Kibdelin C2 is resistant to gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as vancomycin. |
||
BBF-01542 |
Kibdelin D (105997-86-2) Inquiry |
|
Kibdelin D is originally isolated from Kibdelosporangium aridum subsp. largum SKF AAD-609. Kibdelin D is resistant to gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as vancomycin. |
||
BBF-01543 | ||
Kigamicin A is produced by the strain of Amycolatopsis sp. ML-630-mFl. It showed activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 0.025-0.78 μg/mL. |
||
BBF-01544 | ||
Kigamicin B is produced by the strain of Amycolatopsis sp. ML-630-mFl. It showed activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 0.025-0.78 μg/mL. |
||
BBF-01545 | ||
Kigamicin D is produced by the strain of Amycolatopsis sp. ML-630-mFl. It showed activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 0.025-0.78 μg/mL. It also shows effect against L-1210 LB32T and other genera tumor cells with IC50 of 1 μg/mL. |
||
BBF-01546 |
Kinamycin A (35303-12-9) Inquiry |
|
Kinamycin A is produced by the strain of Str. murayamaensis. Kinamycin A has antibacterial and mycobacterial effects, but it has weak activity against gram-negative bacteria. |
||
BBF-01547 |
Kinamycin B (35303-13-0) Inquiry |
|
Kinamycin B is produced by the strain of Str. murayamaensis. Kinamycin B has antibacterial and mycobacterial effects, but it has weak activity against gram-negative bacteria. |
||
BBF-01548 |
Kistamicin A (155683-50-4) Inquiry |
|
Kistamicin A is produced by the strain of Microtetraspora parvasata subsp. kistna. It has antiviral effect, and its ID50 (μg/mL) against influenza virus MDCK cells and herpes simplex virus are respectively 3.6 and 44. It also has anti-gram-positive bacterial effects. |
||
BBF-01549 |
Kistamicin B (155683-51-5) Inquiry |
|
Kistamicin B is produced by the strain of Microtetraspora parvasata subsp. kistna. It has antiviral effect, and its ID50 (μg/mL) against influenza virus MDCK cells and herpes simplex virus are respectively 1.8 and 30. |